Skip to main content

Female DVIU and Urethral Dilation

Urethral dilation is an option for a confirmed female urethral stricture (FUS). Female DVIU has no reliable dedicated outcomes evidence base.[1][12]

For the male counterpart, see DVIU and Urethral Dilation. For paclitaxel-enhanced endoscopic treatment, see Drug-Coated Balloon Therapy.

Guideline Position​

The 2023 AUA guideline states that surgeons may reconstruct FUS using oral mucosal grafts, vaginal flaps, or both ; its supporting text says urethroplasty should be offered given the low efficacy of endoscopic treatment.[1] The 2026 EAU urethral-stricture guideline weakly recommends initial dilation and distinguishes maintenance dilation from definitive cure.[12] The 2026 EAU Non-neurogenic Female LUTS guideline weakly recommends internal urethrotomy with postoperative self-dilation for stricture-related bladder outlet obstruction, with counseling about limited long-term improvement and postoperative incontinence.[13] The EAU urethral-stricture chapter found no outcome study of urethrotomy specifically for anatomical FUS.[12] It weakly recommends against dilation or urethrotomy for bladder outlet obstruction after synthetic midurethral tape because of a theoretical risk of urethral mesh extrusion.[13]

ScenarioFemale-specific guidance
Initial confirmed FUSDilation to 24–41 Fr .[12]
First recurrenceRepeat dilation with planned weekly 16–18 Fr self-dilation, or planned repeat dilation .[12]
Second recurrence, unable to self-dilate or seeking definitive treatmentUrethroplasty .[12]
Isolated short meatal strictureMeatotomy or meatoplasty .[12]

Why Female Strictures Are Different​

FUS is rare, affecting roughly 4–20% of women evaluated for refractory LUTS-related bladder outlet obstruction.[2] Evidence is largely observational, with heterogeneous diagnostic and outcome definitions.[2][3]

Etiology is frequently idiopathic; iatrogenic injury from instrumentation or prior surgery is also important. Other causes include obstetric trauma (especially cephalopelvic disproportion), pelvic trauma, malignancy, radiation, urethral / vaginal atrophy, recurrent infection, and dermatologic disease (lichen planus, lichen sclerosus).[1]

Diagnosis is challenging given the non-specific presentation. Patients may report obstructive LUTS, recurrent UTI, hesitancy, weak stream, urgency-frequency, urethral pain, elevated PVR, or acute retention. Inability to pass even a small catheter is suggestive. VCUG demonstrates the entire female urethra and helps define stricture location and length; cystourethroscopy can identify the distal stricture edge but often requires preliminary dilation and does not define its full extent.[1][8][12] For women with refractory LUTS, the EAU strongly recommends flow rate, post-void residual, and VCUG or videourodynamics.[12]

Anatomic constraints unique to the female urethra:

  • Short urethral length (approximately 4 cm). Less urethra lies between the stricture and the sphincteric complex, so aggressive incision or dilation could threaten continence. New-onset SUI after dilation is reported at 1.4% in the EAU evidence review.[12]

Urethral Dilation​

Dilation is the most commonly performed first-line endoscopic intervention for FUS, often attempted at least once before considering urethroplasty.[3][4]

Technique. Sequential calibrated dilators (sounds or balloon dilators) progressively enlarge the lumen, with the intended caliber chosen from the female-specific guideline range above, performed in clinic or under anesthesia.

Outcomes. Dilation success was 47–49% at mean follow-up of 32–43 months in the Osman and Sarin reviews, but their endpoints differed: Osman counted no further intervention, whereas Sarin required symptom improvement without further instrumentation.[5][6]

Series / ReviewnMean follow-upPooled / reported success
Osman 2013 SR[5]10743 mo~ 47%
Sarin 2021 SR / meta[6]23432 mo49% pooled
Chakraborty 2022 review[4]——41.25% dilation success
Blaivas 2012[7]17 (initial dilation)Not stated for dilation16/17 recurred after initial dilation; follow-up for the remaining patient was not specified
Bouchard 2025 review[3]aggregated—efficacy decreases with each subsequent dilation

Female DVIU​

DVIU involves endoscopic scar incision. Published female incision patterns vary.[12]

Technical considerations specific to the female urethra:

  • The short urethra means even a "short" incision approaches the sphincter; incise conservatively.
  • For isolated meatal disease, consider meatoplasty.
  • Standalone female-DVIU outcome data are scarce; most series pool DVIU with dilation under "endoscopic management."[2][5][8]

Endoscopic Management vs Urethroplasty​

Observational series generally report higher patency after urethroplasty than dilation.

TechniquePooled successMean follow-up
Urethral dilation41–49% across separate reviews32–43 mo in Osman and Sarin[4][5][6]
Flap urethroplasty (vaginal or labial/local groups)91–93% across reviews32–42 mo in Osman and Sarin[4][5][6]
Oral mucosa graft urethroplasty (Sarin: buccal graft)89–94% across reviews15–19 mo[5][6]
Local free graft urethroplasty (Osman: vaginal or labial; Sarin: vaginal)80–87% across reviews15–22 mo[5][6]

Several reviews advise that urethroplasty not be delayed after failure or short-interval recurrence following dilation or DVIU, and some authors advise proceeding after one or at most two failed endoscopic attempts.[3][4][8] The EAU recommends urethroplasty at the second recurrence of female urethral stricture when self-dilation is not feasible or the patient wishes definitive treatment.[12]

Drug-Coated Balloon — Where the Female Evidence Stands​

Optilume drug-coated balloon (DCB) is FDA-approved for obstructive symptoms from anterior urethral strictures of ≤3 cm in adult men.[16] The female evidence remains limited to two case reports, overlapping single-center reports (a conference abstract and a published series with 12 analyzable women), and a separate nine-woman multicenter retrospective series. In the single-center publication, 11/12 were free from recurrence and repeat intervention at analysis (mean follow-up 12 months, range 6–41).[14] Use remains exploratory, and patients are counseled accordingly.[9][10][11][14][15]

Complications and Adjuncts​

  • Recurrence is the main limitation, and the chance of success falls with each repeat endoscopic attempt.
  • De novo SUI is the main continence concern. A review of female stricture interventions reported mild to moderate de novo incontinence in 9.43% across its surgical treatment categories, with most recovering after pelvic floor exercises.[3][4] The EAU review reports new-onset SUI in 1.4% after dilation.[12]
  • Other complications: urethral bleeding, false passage, worsening peri-urethral fibrosis. Repeat instrumentation itself is a recognized cause of stricture progression.[1]
  • Self-dilation adjunct. Ongoing catheterization burden is discussed, and maintained patency is distinguished from cure. The female-specific recurrence pathway above applies.[1]
  • Intralesional injection. The AUA guideline discusses mitomycin C and corticosteroid adjuncts to DVIU, but the EAU female-stricture review found no urethrotomy outcome study specific to female FUS. Evidence is insufficient to determine benefit or safety of these injections in women with FUS.[1][12]

Summary​

Confirm an anatomical stricture before intervention. Counsel about dilation's limited durability, self-dilation as maintenance, and urethroplasty as a definitive option.[1][3][4][5][6][8]

References​

1. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482.

2. Turchi B, Lumen N, Verla W, Waterloos M. Female urethral stricture disease: a narrative review on diagnosis, surgical techniques and outcomes. Int J Impot Res. 2026;38(4):286-295. doi:10.1038/s41443-025-01079-6.

3. Bouchard B, Campeau L. Surgery for female urethral stricture. Neurourol Urodyn. 2025;44(1):51-62. doi:10.1002/nau.25358.

4. Chakraborty JN, Chawla A, Vyas N. Surgical interventions in female urethral strictures: a comprehensive literature review. Int Urogynecol J. 2022;33(3):459-485. doi:10.1007/s00192-021-04906-8.

5. Osman NI, Mangera A, Chapple CR. A systematic review of surgical techniques used in the treatment of female urethral stricture. Eur Urol. 2013;64(6):965-973. doi:10.1016/j.eururo.2013.07.038.

6. Sarin I, Narain TA, Panwar VK, et al. Deciphering the enigma of female urethral strictures: a systematic review and meta-analysis of management modalities. Neurourol Urodyn. 2021;40(1):65-79. doi:10.1002/nau.24584.

7. Blaivas JG, Santos JA, Tsui JF, et al. Management of urethral stricture in women. J Urol. 2012;188(5):1778-1782. doi:10.1016/j.juro.2012.07.042.

8. Waterloos M, Verla W. Female urethroplasty: a practical guide emphasizing diagnosis and surgical treatment of female urethral stricture disease. Biomed Res Int. 2019;2019:6715257. doi:10.1155/2019/6715257.

9. Stuehmeier J, Jelisejevas LA, Kink P, Gulacsi A, Horninger W, Rehder P. Optilume drug-coated balloon dilation in complex female urethral stricture. Urol Case Rep. 2022;41:101987. doi:10.1016/j.eucr.2021.101987.

10. Jelisejevas LA, Tulchiner G, Stuehmeier J, et al. PD05-02 Optilume drug-coated balloon dilation in the treatment of female urethral stricture disease. J Urol. 2025;213(5S):e108. doi:10.1097/01.JU.0001109760.63452.97.02.

11. Thomas HS, Stern N, Neu S, Herschorn S. Drug-coated balloon dilation for female urethral stricture. Urol Case Rep. 2025;59:102985. doi:10.1016/j.eucr.2025.102985.

12. European Association of Urology. Urethral Strictures: Disease Management in Females. 2026. Official guideline.

13. European Association of Urology. EAU Guidelines on Non-neurogenic Female LUTS: Disease Management. 2026. Official guideline

14. Jelisejevas LA, Tulchiner G, Kink P, Rehder P. "Does Optilume drug-coated balloon dilation compromise female sphincter function?" Int Urol Nephrol. 2025;57(10):3215-3217. doi:10.1007/s11255-025-04513-2

15. Carracedo D, Belkahia G, Sánchez-Gallego MD, et al. "Multicentric preliminary experience and clinical outcomes of female urethral dilation using a paclitaxel-coated balloon." Int Urogynecol J. 2026;published online May 20. doi:10.1007/s00192-026-06693-6

16. U.S. Food and Drug Administration. Optilume Urethral Drug Coated Balloon (P210020): Instructions for Use. 2021. FDA labeling.